Murex losses continue due to litigation costs:
This article was originally published in Clinica
Canadian company International Murex Technologies reported sales of $50.4 million for the six months ended June 30th, 1996, up 6% on the same period in the previous year. The company's net loss was $1.3 million, compared with $3.2 million last year, which reflects the decreasing legal costs relating to HCV patent litigation against Chiron (see Clinica No 632, p 13). The company expects to return to profitability in 1996. Murex has now begun court proceedings against Abbott for patent infringement of its particle bound binding component immunoassay (see Clinica No 713, p 1).
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.